Inhibition of striatal dopamine release by the L-type calcium channel inhibitor isradipine co-varies with risk factors for Parkinson's
Katherine R. BrimblecombeiD, Natalie Connor‐RobsoniD, Carole J. R. BatailleiD, Bradley M. RobertsiD, Caitlin J. Gracie, Bethan O’ConnoriD, Rebecca te Water NaudéiD, Gayathri KarthikiD, Angela J. RusselliD, Richard Wade‐MartinsiD, Stephanie Jane CraggiD
Abstract
Ca2+ entry into nigrostriatal dopamine (DA) neurons and axons via L-type voltage-gated Ca2+ channels (LTCCs) contributes respectively to pacemaker activity and DA release, and has long been thought to contribute to vulnerability to degeneration in Parkinsons disease. LTCC function is greater in DA axons and neurons from substantia nigra pars compacta than from ventral tegmental area, but this is not explained by channel expression level. We tested the hypothesis that LTCC-control of DA release is governed rather by local mechanisms, focussing on candidate biological factors known to operate differently between types of DA neurons and/or be associated with their differing vulnerability to parkinsonism, including biological sex, -synuclein, DA transporters (DATs), and calbindin-D28k (Calb1). We detected evoked DA release ex vivo in mouse striatal slices using fast-scan cyclic voltammetry, and assessed LTCC support of DA release by detecting the inhibition of DA release by the LTCC inhibitors isradipine or CP8. Using genetic knockouts or pharmacological manipulations we identified that striatal LTCC support of DA release depended on multiple intersecting factors, in a regionally and sexually divergent manner. LTCC function was promoted by factors associated with Parkinsonian risk, including male sex, -synuclein, DAT, and a dorsolateral co-ordinate, but limited by factors associated with protection i.e. female sex, glucocerebrosidase activity, Calb1, and ventromedial co-ordinate. Together, these data show that LTCC function in DA axons, and isradipine effect, are locally governed and suggest they vary in a manner that in turn might impact on, or reflect, the cellular stress that leads to parkinsonian degeneration. O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=133 SRC="FIGDIR/small/186411v2_ufig1.gif" ALT="Figure 1"> View larger version (21K): org.highwire.dtl.DTLVardef@1ccc783org.highwire.dtl.DTLVardef@13e7296org.highwire.dtl.DTLVardef@d4e3d3org.highwire.dtl.DTLVardef@b9427b_HPS_FORMAT_FIGEXP M_FIG C_FIG
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 10
- FWCI
- 1.35
- Field percentile
- top 19%
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Comparing tonic and phasic calcium in the dendrites of vulnerable midbrain neurons
Rita Chen, Rebekah C. Evans·bioRxiv·Aug 28, 2023
- Sex- and age-dependent control of dopamine function by LRRK2, and rapid reversal of dopamine release deficits in the LRRK2-G2019S knock-in mouse model of Parkinson's Disease.
Christina Gentle, Anusha Kamesh, … Austen J. Milnerwood·bioRxiv·Oct 16, 2026
- Alterations in the intrinsic properties of striatal cholinergic interneurons after dopamine lesion and chronic L-DOPA
Se Joon Choi, Thong Chi Ma, … Un Jung Kang·eLifePeer-reviewed·Jul 20, 2020
- Dopamine 2 receptor ablation from cholinergic neurons attenuates L-DOPA induced dyskinesias.
Santiago Uribe‐Cano, Lauren B. Malave, Andreas H. Kottmann·Frontiers in Aging NeurosciencePeer-reviewed·May 12, 2026
- Gabapentinoids promote striatal dopamine release and rescue multiple deficits of a mouse model of early Parkinson's
Katherine R. Brimblecombe, Adam Loyd Harris, … Stephanie Jane Cragg·bioRxiv·Sep 16, 2025
- Dopaminergic inhibition of the inwardly rectifying potassium current in direct pathway medium spiny neurons in normal and parkinsonian striatum
Qian Wang, Yuhan Wang, … Fu‐Ming Zhou·Brain SciencesPeer-reviewed·Sep 12, 2025